Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk to expand China R&D

Novo Nordisk is to double the size of its R&D centre in China by 2015

Novo Nordisk is to double the size of its R&D centre in Beijing, China by 2015.

The diabetes specialist said the level of employees at the centre will increase from 100 to 200, with a focus on creating a new Diabetes Research Unit in the country.

 

A picture of a building housing a Diabetes Research Unit in China

Novo Nordisk R&D centre in China

 

"By doubling the current staff at our R&D centre, Novo Nordisk acknowledges the achievements of the Chinese staff since the centre was established in 1997," said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Denmark-based Novo Nordisk.

"And once again, we demonstrate our long term commitment to take part in the scientific and technological development of China, while at the same time helping Novo Nordisk to get access to the tremendous resource of talents, ideas and innovation in China."

Since its establishment, the R&D centre has focused on building expertise in protein engineering and purification, as well as creating and improving monoclonal antibodies.

The expansion will see Novo Nordisk research biopharmaceutical approaches to develop new treatments against diabetes.

The company said the R&D team in China "will eventually take part in all aspects of drug discovery, from innovation to developing drug candidates for clinical studies in humans."

14th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....

Infographics